This week we highlighted findings from recently published cost-effectiveness studies:
- Patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics: Two alternative approaches are proposed that use patient-level health-related utility and costs data to produce patient-centered cost-effectiveness. (4)
- Increasing access to pregnancy tests highly effective at community level: Addition of low cost, easy-to-use urine pregnancy tests to maternal and reproductive services package offered in community health centers in Madagascar, Ethiopia, and Malawi, may offer a cost-effective solution to increase access and utilization of life-saving health services. (9)
- Economic modeling of different interventions in women with BRCA1/2 mutations: Surgical preventive options for German women with BRCA1/2 mutation carriers result in a substantial gain of QALY/life years and potential cost savingswhen compared to no surgical prevention. (12)
See below for a full list of all cost-utility studies and selected reviews and editorials published April 3-7, 2017. To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry. Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Berger BA, Cossio A, Saravia NG, Castro MD, Prada S, Bartlett AH, Pho MT. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005459. PMID: 28384261.
2: Chan AY, Vadera S. Implementation of interdisciplinary neurosurgery morning huddle: cost-effectiveness and increased patient satisfaction. J Neurosurg. 2017 Apr 7:1-4. PMID:28387619.
3: Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One. 2017 Apr 5;12(4):e0175189. PMID: 28380022.
4: Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, Mullins CD.Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Apr 4. PMID: 28378193.
5: Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecol Oncol. 2017 Apr 5. PMID: 28390820.
6: Itzkowitz SH, Ahlquist DA. The Case for a Multitarget Stool DNA Test: A Closer Look at the Cost Effectiveness Model. Gastroenterology. 2017 Apr 3.PMID: 28384447.
7: Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Apr 5:1-12. PMID: 28294642.
8: Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, Humphries
SE. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017 Apr 6. PMID: 28387827.
9: Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health Policy Plan. 2017 Apr 5. PMID: 28387867.
10: Lince-Deroche N, Fetters T, Sinanovic E, Devjee J, Moodley J, Blanchard K. The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa. PLoS One. 2017 Apr 3;12(4):e0174615. PMID: 28369061.
11: Liu TW, et al. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc. 2017 Apr 4. PMID: 28389143.
12: Müller D, et al. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ. 2017 Apr 5. PMID: 28382503.
13: Nedelcu M, Manos T, Gagner M, Eddbali I, Ahmed A, Noel P. Cost analysis of
leak after sleeve gastrectomy. Surg Endosc. 2017 Apr 4. PMID: 28378080.
14: Noben C, et al. Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis. J Occup Health. 2017 Apr 5. PMID: 28381814.
15: Qiu J, Yu C, Ariyaratne TV, Foteff C, Ke Z, Sun Y, Zhang L, Qin F, Sanderson G. Cost-Effectiveness of Pediatric Cochlear Implantation in Rural China. Otol Neurotol. 2017 Apr 4. PMID: 28379918.
16: Ravikumar VK, et al. Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord. 2017 Apr 3. PMID: 28370272.
17: Shim E. Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model. PLoS One. 2017 Apr 5;12(4):e0175020. PMID: 28380060.
18: Silver RM, Einerson BD. Cost-effectiveness analysis and Obstetrics: The time has come. BJOG. 2017 Apr 6. PMID: 28383770.
19: Takura T, Takei T, Nitta K. Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan. Sci Rep. 2017 Apr 7;7:46036. PubMed PMID: 28387313.
20: Thilly N, et al. Cost-effectiveness of home telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized controlled trial (eNephro): rationale and study design. BMC Nephrol. 2017 Apr 5;18(1):126. PMID: 28381266.
21: Ting EE, Sander B, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017 Apr 4;35(15):1828-1843. PMID: 28284681.
22: Wikman-Jorgensen PE, et al. Microscopic observation drug-susceptibility assay vs Xpert(®) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Trop Med Int Health. 2017 Apr 5. PMID: 28380276.